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ABSTRACT 51 
Despite international guidelines, optimal delivery models of late effects (LE) services for HSCT 52 
patients are unclear from clinical, organisational and economic viewpoints. To scope current LE 53 
service delivery models within the UK-NHS, in 2014 we surveyed the 27 adult allogeneic HSCT 54 
centres using a 30 question online tool, achieving a 100% response rate.  55 
Most LE services were led and delivered by senior physicians (>80% centres). Follow-up was usually 56 
provided in a dedicated allograft or LE clinic for the first year (>90% centres), but thereafter attrition 57 
meant only ~50% of patients were followed after 5 years. Most centres (69%) had an SOP for long-58 
term monitoring but access to a LE Multi-Disciplinary Team was rare (19% centres). Access to 59 
medical specialities necessary for LE management was good, but specialist interest in long-term 60 
HSCT complications was uncommon. Some screening (endocrinopathy, cardiovascular) was near 61 
universal, but other areas were more limited (mammography, cervical smears). Funding of extra 62 
staff and investigations were the most commonly perceived barriers to implementation of LE 63 
services.  64 
This survey shows variation in the long-term follow-up of allogeneic HSCT-survivors within the UK-65 
NHS and further work is warranted to optimise effective, sustainable and affordable models of LE 66 
service delivery among this group. 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
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INTRODUCTION 77 
Since the first recorded allogeneic haematopoietic stem cell transplant (HSCT) using a donor other 78 
than an identical twin in 1968,
1
 the worldwide annual number of patients undergoing this procedure 79 
has risen to more than 23,500.
2
 Over the same period improvements in conditioning regimens
3
 (e.g. 80 
reduced intensity conditioning [RIC]) and supportive care (e.g. management of infectious 81 
complications
4,5
 and graft versus host disease [GVHD]),
6
 as well as widening of indications to include 82 
non-malignant disorders (e.g. haemoglobinopathies)
7
 and availability of alternative HSCT donor 83 
sources
8
 have led to increasing numbers of long-term survivors (i.e. alive two years post-allogeneic 84 
HSCT).
9
 However, with improved survival, even in the absence of disease relapse, normal life 85 
expectancy is not restored:
10
 Survivors are susceptible to organ dysfunction
11,12
 (aside from chronic 86 
GVHD) and subsequent malignancies
13
 resulting in a significant morbidity burden
14
 and premature 87 
mortality. In addition to physical sequelae, allogeneic HSCT survivors are at risk of psychological 88 
complications, including post-traumatic stress disorder,
15
 which may have major impact on quality of 89 
life.
16
 90 
The increased morbidity and non-relapse mortality exhibited by long-term allogeneic HSCT survivors 91 
led to recognition of the need for long-term follow-up and screening of this patient population to 92 
allow pre-emptive action to try and mitigate the increased risks.  Accordingly, the Center for 93 
International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and 94 
Marrow Transplantation (EBMT) and American Society for Blood and Marrow Transplantation 95 
(ASBMT) produced consensus recommendations on the subject in 2006
17
 (subsequently enshrined in 96 
JACIE [sixth edition] standard B7.6.8).
18
 These were updated in 2011 with additional representation 97 
from the Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant 98 
Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow 99 
Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea 100 
(SBTMO)to ensure their international applicability.
19
 Owing to lack of prospective (randomised) 101 
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controlled trials in this area these are based on retrospective studies, non-transplant data and expert 102 
consensus opinion, but nevertheless are considered to be the most comprehensive guidance 103 
available for management of this patient population. 104 
 105 
However, there is little consensus on how the international guidelines are best applied and data is 106 
limited as to the extent of their implementation.
20,21
 On behalf of the British Society of Blood and 107 
Marrow Transplantation (BSBMT), we therefore sought to establish how services for late post-108 
transplant effects were delivered by UK adult allogeneic HSCT centres within the governmentally 109 
funded National Health Service (NHS). Although ultimately all NHS services are state funded, HSCT 110 
procedures are nationally commissioned while care from day 100 post-transplant is locally 111 
commissioned.
22
  112 
 113 
MATERIALS & METHODS 114 
Survey Development & Design 115 
A 30 question web-based survey was developed following consultation with senior UK allogeneic 116 
HSCT physicians and nurses with an interest in LE services for allogeneic HSCT survivors and 117 
representatives of organisations concerned with allogeneic HSCT patient welfare (e.g. Anthony 118 
Nolan). Questions were designed around four themes; service organisation, access to other 119 
specialist services necessary for the management of LE, multi-disciplinary team (MDT) provision and 120 
patient engagement, service evaluation and improvement. Most questions required respondents to 121 
select one/several options from a range of possibilities although, where relevant, there was the 122 
ability to enter free text. The survey was piloted with members of the BSBMT-Clinical Trials 123 
Committee (CTC) prior to wider circulation.  124 
For the purposes of this survey the National Cancer Institute definition of Late Effects was used:  ?A 125 
health problem that occurs months or years after a disease is diagnosed or after treatment has 126 
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ended. Late effects may be caused by cancer or cancer treatment. They may include physical, 127 
mental, and socŝĂůƉƌŽďůĞŵƐĂŶĚƐĞĐŽŶĚĐĂŶĐĞƌƐ ? ?23 The definition was extended to patients with 128 
non-malignant diseases who had been treated with allogeneic transplantation, where LE may be 129 
caused by the disease or disease treatment. In several questions respondents were asked to provide 130 
the percentage of patients in whom a particular activity took place; this was intended to be a best 131 
estimate for surviving patients at that time point rather than an exact calculated figure. The survey is 132 
available in the Supplementary Information. 133 
Survey Administration 134 
The survey was circulated via the BSBMT to programme directors of the 27 adult UK NHS allogeneic 135 
HSCT centres with an invitation for the most appropriate personnel to complete (medical or 136 
nursing). One generic reminder was sent to all centres after which individual approaches were made 137 
by the survey authors to non-responding centres. The survey was completed during 2014. Statistical 138 
associations between overall allogeneic HSCT centre activity, co-existent paediatric HSCT activity in 139 
the centre and the long-term follow-up patterns were explored using 2014 activity data from the 140 
BSBMT registry.
24
   141 
 142 
RESULTS 143 
Centre Demographics 144 
A 100%
a
 response rate was achieved, with most surveys (85%) completed by allogeneic HSCT 145 
physicians (Table 1). All centres were engaged with the JACIE accreditation process; 82% were fully 146 
accredited (Table 1) having completed a median of two accreditation cycles. The lower age of 147 
allogeneic HSCT recipients ranged from 16-20 years (Table 1) with almost half of adult centres (46%) 148 
                                                          
a
 Although all centres (27) submitted a response, some centres omitted to answer particular questions; results 
from these questions are reported as percentages of the responding centres with the number or responses 
used indicated by n=x. 
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performing allogeneic HSCT in patients under 18 years of age (both the EBMT and UK legal definition 149 
of an adult).   150 
 151 
LE Service Organisation    152 
The LE service was most frequently organised and administered by medically qualified staff (88% 153 
centres) with the remainder being nurse led (Table 1). Most LE services were delivered in either a 154 
dedicated clinic (63%) or within the general allogeneic HSCT clinic (33%) with only one centre 155 
routinely reviewing patients in a general haematology clinic (Table 1). Figure 1a shows there was an 156 
attrition rate over time in the percentage of surviving post-allogeneic HSCT patients being followed 157 
up by the transplanting centre. Although 96% of centres followed up all patients from day 100 to 1 158 
year, by 5 years post-allogeneic HSCT only 48% centres routinely reviewed all patients and 11% of 159 
centres were actively following up fewer than half their patients. In some centres part of this 160 
attrition was due to formal discharge of patients at 5 years post-allogeneic HSCT back to either their 161 
referring non-HSCT-performing haematology centre or primary care physician if they had received a 162 
RIC HSCT and were free of complications including GVHD. Other patients however were lost to 163 
follow up (e.g. moved away geographically from the transplanting centre). Centre size and co-164 
existent paediatric activity were not significantly associated with long-term follow-up patterns for 165 
adults (see Supplementary Table 1). 166 
A standard operating procedure (SOP) for long-term monitoring of LE (as indicated by JACIE [sixth 167 
edition] standard B7.6.8)
18
 was available in 69% of responding allogeneic HSCT centres (n=26), with 168 
39% of these centres having audited their adherence to the policy (Table 1). All SOPs included the 169 
physical assessment of patients but only 28% made any reference to psychological evaluation (Table 170 
1). The use of a standard template to communicate treatment summaries and potential 171 
complications to other health care professionals (as recommended by the National Cancer 172 
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Survivorship Initiative; example template available at http://www.ncsi.org.uk/wp-173 
content/uploads/Treatment-Summary-Template1.doc) was undertaken in 41% of centres (Table 1). 174 
Access to Specialist Services 175 
Figure 1b illustrates the range of specialist services available to allogeneic HSCT centres (n=26) in the 176 
management of LE. All the medical specialities were accessible to >80% of responding centres. 177 
Easiest access was reported to endocrinology, sexual health and respiratory services (96%, 93% and 178 
93% centres respectively) while more limited, but still good, access was available for oral medicine 179 
and dentistry services (81% centres). Access to allied health specialities was more varied: Although 180 
most centres (89%) had access to a dietician, availability of physiotherapy, occupational therapy and 181 
psychology support was not universal with only 62%, 65% and 69% of centres being able to access 182 
these respectively.  183 
In contrast to the overall good access to specialist services for allogeneic HSCT survivors, the number 184 
of centres reporting personnel in these specialities with an interest in the LE of allogeneic HSCT was 185 
low (Figure 1b). With the exception of key workers and clinical nurse specialists, the majority of 186 
whom had an interest in HSCT LE as might be expected (94% and 84% respectively), fewer than 50% 187 
of centres reported personnel with a specialist interest among any medical or allied health speciality. 188 
Greatest interest was seen in specialities likely to have the most contact with post-HSCT patients; 189 
endocrinology, dietetics, sexual health and respiratory medicine (46%, 39%, 39% and 35% 190 
respectively).    191 
Respondents reported variable compliance with screening recommendations in the international 192 
guidelines:
19
 Although routine rates of implementation of endocrine and cardiovascular screening 193 
were good (89% and 78% respectively), lower rates of cervical screening and mammography were 194 
reported (52% and 48% respectively) despite the existence of established National Breast
25
 and 195 
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Cervical Cancer
26
 Screening Programmes within the UK for the general population (Table 1). Only 196 
30% of centres found it easy to access these National Screening Programmes.  197 
There was near universal implementation of revaccination post allogeneic HSCT (96% centres) 198 
although only 23% of centres undertook antibody testing in the majority of patients (>90%) to 199 
monitor vaccine efficacy (Table 1). Among the remainder of centres there was variation in post-200 
vaccine antibody response monitoring; some never undertook such testing while others targeted it 201 
to patients with recurrent infections or those felt to have a particularly high infection risk (e.g. HLA 202 
mismatch, alternative stem cell donor source). Post-allogenic HSCT vaccination practice has been the 203 
subject of a separate more detailed BSBMT survey.
27
  204 
MDT Provision 205 
Only 19% of centres had access to a specific LE MDT (Table 1) and where available this was mostly 206 
(60% MDTs) limited to patients under 25 years (data not shown). Where LE MDTs were available 207 
membership varied: Although all included a senior haematologist and clinical nurse specialist there 208 
was less regular support from other speciality physicians (including paediatrics), psychologists and 209 
social workers.  210 
Patient engagement, service evaluation and improvement 211 
A patient support group whose target audience included long-term allogeneic HSCT survivors was 212 
available in 41% of centres (Table 1) variably led by nurses, social workers, psychologists or patients 213 
themselves. Where available most (73%) met at least every 3 months (data not shown). Given a 214 
central theme of JACIE standards relates to education, service evaluation and audit in order to bring 215 
about service improvement, centres were asked how often they engaged in such activities which 216 
included some aspect of LE monitoring or care. At least one formal educational event covering an 217 
aspect of LE management had been delivered by 67% of centres in the preceding three years, while 218 
a clinical audit or service evaluation had been performed by 59% of centres (n=26) over the same 219 
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period. However, only 41% of centres had sought patient input regarding their satisfaction with LE 220 
and long-term follow-up arrangements over this time (Figure 1c).  221 
During consultations with relevant stakeholders prior to development of this survey it became 222 
apparent there were a number of differences between the realities of the LE services provided by 223 
allogeneic HSCT centres and what they felt should be available. In order to ascertain the 224 
impediments to LE service delivery, centres rated potential barriers to implementation of an 225 
idealised service (suggested both by the survey authors and in the literature).
28
 These are 226 
summarised in figure 1d, and the three highest rated obstacles all relate to finance/resource 227 
provision, with lack of funding for psychological support considered to be the greatest limitation.  228 
 229 
DISCUSSION 230 
To our knowledge, this is the first survey examining the practical provision of long-term follow-up 231 
and LE services for allogeneic HSCT patients across a national healthcare system. It provides a 232 
comprehensive view of how care is being delivered to this complex patient population. Despite 233 
national publically funded delivery of HSCT care, the survey demonstrates variability in almost every 234 
aspect of the service.  Some variation may reflect the historical, opportunistic way LE services have 235 
evolved in individual centres. Although we were unable to show any relationship with centre activity 236 
and co-existent paediatric activity, other factors such as centre specialisation, geography and 237 
referral base may be contributory and further work is required in this area.   238 
This survey highlighted some positives in that all centres had a LE service and most had a standard 239 
operating procedure outlining its processes. Additionally, most centres reported good local 240 
availability of a range of medical and some allied health specialities necessary for the management 241 
of LEs. Free text comments indicated many centres are engaged in active development of their LE 242 
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service through the appointment of new personnel and by establishing separate clinics (in some 243 
cases combined with cGVHD management). 244 
However, this survey also emphasised general weaknesses and limitations of LE services throughout 245 
the UK, including limited access to LE MDTs. Despite good provision of most other specialities 246 
necessary for the management of LE within tertiary NHS hospitals, most specialists delivering this 247 
care did not have a particular interest in post-allogeneic HSCT care. Although national screening 248 
programmes exist for both breast
25
 and cervical cancer
26
 detection, enrolling post-allogeneic HSCT 249 
patients in these outside of standard age-dictated times was problematic. Both these points 250 
highlight a need for better engagement and education of health care professionals outside of 251 
haematology.
21,29
 252 
This survey also demonstrates a bias of LE services towards screening activities within the normal 253 
remit of transplant physicians and associated personnel: Assessment of endocrine and 254 
cardiovascular function was generally carried out well while in contrast, implementation of 255 
specialised services where transplant physicians have less control (e.g. mammography, cervical 256 
screening) was much poorer. In common with other post-HSCT populations,
30
 there was limited 257 
access to specialist psychological services in this susceptible population.
15
 Only 28% of LE SOPs had 258 
any reference to psychological function despite international guidelines and recommendations.
19
  259 
The emphasis of many LE services on the management of medical symptoms may not always 260 
correlate with patient concerns: A recent audit of patient-reported symptoms in a nurse-led post-261 
HSCT LE clinic indicated that the most prevalent problems were pain, sleep disturbance, fatigue and 262 
sexual function concerns,
31
 none of which are easily attributable to a particular physiological system. 263 
The apparent misalignment of the LE service agenda
32
 and patient concerns
33
 is something that 264 
could be addressed by better engagement of patients through support groups and quality of life
34
 or 265 
service satisfaction surveys.
35
 Ultimately patient interests are likely to be best served with long-term 266 
follow-up LE services led and delivered by a combination of medical and nursing staff with the 267 
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flexibility for patients to be seen by either group of health care professionals depending on their 268 
specific symptoms and needs. Perhaps as expected, all allogeneic HSCT centres identified lack of 269 
financial resources as the major constraint on the implementation of ideal services, particularly with 270 
regards to the delivery of psychological support.  271 
As with any survey, it is necessary to exercise some caution with result interpretation. Firstly centres 272 
can only report activities they have direct control over: The survey suggests that patients from only 273 
30% of centres undergo lifelong follow-up (i.e. beyond 10 years) as recommended by international 274 
guidelines
19
. However, it is possible that many of the remaining 70% of centres refer patients  back 275 
to either their referring hospital or primary care provider to follow a recommended late effects 276 
surveillance plan; activity which would not necessarily be known to the transplanting centre.  277 
Secondly, the results inevitably reflect what a centre reports to be doing rather than what has been 278 
independently verified as taking place. Nevertheless, given the deficiencies in the LE service reported 279 
by almost all centres, it seems likely that the responses represent a consistent summary of service 280 
provision and operation. Finally, although this survey documents variation in practice it does not 281 
provide information about how this affects patient outcome: In order to optimise long-term follow-282 
up and LE service provision it is necessary to collect data on patient outcomes with the different 283 
models of care delivery.  284 
In summary, this survey provides valuable feedback on the current delivery of LE service provision 285 
for post-allogeneic HSCT survivors within the UK, which is likely to be applicable to other healthcare 286 
systems internationally. It provides information of where international guidelines and 287 
recommendations
19
 are being easily met and areas where services are deficient and require 288 
additional resource investment. Further research into which models of care provide the most 289 
clinically effective and cost-efficient means of service delivery is warranted. 290 
 291 
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FIGURE LEGEND 
Figure 1 
A demonstrates the proportion of patients followed up by the transplanting centre at varying time 
points post-allogeneic HSCT. 
B illustrates the percentage of allogeneic HSCT centres with access to specialist services involved in 
the long term follow up and LE care of patients who have undergone allogeneic HSCT. The 
percentage of centres with personnel delivering these specialist services with an interest in the 
complications of allogeneic HSCT are indicated by the pale grey bars. 
C shows the percentage of allogeneic HSCT centres which have held educational events, clinical 
audit/service evaluation or patient questionnaire/satisfaction survey over the last 3 years and the 
number of such events undertaken. 
D ŝŶĚŝĐĂƚĞƐƚŚĞŽƉŝŶŝŽŶŽĨĂůůŽŐĞŶĞŝĐ,^dĐĞŶƚƌĞƐĂƐƚŽƚŚĞďĂƌƌŝĞƌƐƚŽŝŵƉůĞŵĞŶƚĂƚŝŽŶŽĨƚŚĞ ?ŝĚĞĂů ?
late effects service. Respondents were asked to rate potential barriers on a numerical scale from 0-
10 where 0 represents no barrier while 10 is a major barrier to implementation. 
 
 
 
 
 
 
